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ABSTRACT
Effect of Oral Lipids on Blood Glucose
Tyler R. Knisley

Diabetes mellitus is a disease in which insulin hormone is ineffective or no longer
produced. Multiple pathophysiologies can cause either insulin dependent diabetes
mellitus (IDDM) or insulin independent diabetes mellitus (IIDM), which can lead to
chronic hyperglycemia and an array of short and long term health risks. Prior research
has shown that IDDM patients have dyslipidemia, and experiments infusing lipids
directly into the blood result in heightened insulin resistance. The hypothesis that
dyslipidemia increases insulin resistance was tested by performing oral glucose tolerance
tests across three treatment conditions. Participants were nondiabetic college-aged
students. Data from a control group was gathered and analyzed against a lipid and
carbohydrate treatment. The lipid group showed the greatest increase in glucose level at
any single time period, but the carbohydrate group remained steadily elevated throughout
the three hour testing window. Analysis of the data showed the only significant difference
existed between the carbohydrate and dextrose treatments, meaning the original
hypothesis could not be supported. For future testing, it is recommended that each test
group contain all the same subjects and a longer fasting period is given after the
carbohydrate treatment is consumed. The research and experiments were condensed into
a lab protocol so students enrolled in BMED 460 may further extend their knowledge of
diabetes and help lead the future of treatment and device innovation.

Keywords: Insulin Independent Diabetes Mellitus, Dyslipidemia, Hyperglycemia,
Insulin Resistance
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Chapter 1. Introduction
Diabetes mellitus affects over 25 million Americans and its prevalence is
increasing as people are living longer [1]. Over one quarter of these cases are found in
senior patients older than 65, and across all age groups, it is estimated that over 7 million
affected individuals have yet to be diagnosed [1]. There are two common types of
diabetes: insulin dependent diabetes mellitus (IDDM), also known as type 1, and insulin
independent diabetes mellitus (IIDM), also known as type 2. Insulin is a hormone that
activates a signaling cascade which allows for the transport of glucose molecules from
the blood stream and interstitium to myofibers and adipocytes. These tissues may then
utilize the glucose for cell growth and survival. Both forms of diabetes result in improper
glucose transport and hyperglycemia (elevated blood sugar levels). Over time, this
chronic hyperglycemia causes major health complications, including kidney failure,
lower limb amputation, blindness, stroke, and heart disease [1]. Overall, diabetes is the
seventh-highest cause of death in the United States.

Background
There are three forms of diabetes, IDDM, IIDM, and gestational, each with
differing etiologies and pathophysiologies. IDDM, also known as “Juvenile Diabetes,”
occurs when patients are no longer able to produce insulin. Scientists believe this is
caused by a combination of genetics and environmental factors, specifically a viral
infection [2]. These factors trigger an autoimmune disease that slowly but permanently
attack the insulin-producing β-cells of the pancreas [3]. Once they are destroyed, the
pancreas produces minimal to zero new insulin for the rest of the patient’s life. This
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absence of insulin prevents glucose from being properly transported to muscle and
adipose tissue, and can cause hyperglycemia. IDDM may develop at any age, but is most
often diagnosed in children or young adults [4].
IIDM is the most common form of diabetes, and coupled with the growing obesity
problem in America, is evolving into an “epidemic.” In 2010, the Center for Disease
Control and Prevention estimated that over 79 million Americans had prediabetes [1].
While a diagnosis of insulin resistance (prediabetes) does not guarantee these patients
will develop IIDM, it indicates their blood glucose is consistently higher than normal and
if left untreated, the condition is likely to progress [5].
The fat, liver, and muscle cells of IIDM patients do not properly respond to
insulin. Due to this, sugar remains in the blood stream and is not properly utilized by
these specific cells [6]. IIDM is often called “Insulin Resistant Diabetes” because of this.
This buildup of sugars, or hyperglycemia, slowly increases the risk of additional
complications occurring. Risks of developing IIDM depend on family history, excess
body weight, and dietary habits involving high lipid intake.
The least common and most temporary type is gestational diabetes, which can
occur around week 20 of pregnancy [7]. This is thought to be caused by the increased
levels of estrogen, cortisol, and human placental lactogen, which can inhibit insulin from
initiating glucose transport [8]. Gestational diabetes is often addressed without the need
for medication or insulin shots. The most important concern is monitoring fetal health by
measuring the fetal body size and heart rate to ensure it is developing correctly [7].
Women who become pregnant at older ages and who are overweight before conception
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are at higher risks of developing this condition. However, unless the mother was diabetic
before her pregnancy, this disorder normally disappears after parturition.

Insulin and Glucose Signaling Pathways
The etiology of diabetes can be explained by the interactions between insulin and
glucose molecules, which are shown in Figure 1. Insulin is a hormone produced by the
endocrine portion of the pancreas, and its release is stimulated by postprandial
hyperglycemia. The endocrine portion is composed of millions of cell clusters called
Islets of Langerhans. Over 75% of these cell clusters are β-cells, which are responsible
for producing insulin molecules and then releasing them from the pancreatic islets [9].
Insulin’s main metabolic function is activating the signaling cascade that causes glucose
transport to skeletal myofibers and adipocytes, as well as reducing gluconeogenesis in the
liver [10].

Figure 1: Diagrams of a simple glucose (C6H12O6) and complex insulin molecule [11, 12].
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Glucose stimulates insulin secretion by entering a β-cell
cell via a GLUT-2
GLUT transporter
[9]. Inside the β-cell it is phosphorylated by a glucokinase into glucose-6
6-phosphate
(G6P). Additional glucose increases the ATP:ADP ratio and closes ATP--sensitive
potassium channels. The closing of these channels causes the β-cell
cell membrane
membra to
depolarize, opening calcium
calcium-ion channels. This pathway, shown in Figure 2,
2 causes
exocytosis of insulin secreto
secretory granules from the β-cell into the bloodstream [9].

Figure 2: Signaling
ignaling pathway for insulin secretion. Glucose enters the β-cell
cell via the GLUT-2
GLUT
transporter. This process eventually leads to insulin cellss being secreted into the body [9].

Once insulin is secreted, it stimulates glucose transport from the blood to
myofibers and adipocytes
adipocytes. This pathway is initiated when insulin binds to a specific type
of receptor tyrosine kinase (RT
(RTK)
K) known as an insulin receptor, which is found in almost
all cells of the body [13].. The β subunits of this RTK phosphorylate tyrosine residues,
residues
which in turn recruit insulin receptor substrates (IRS)
(IRS). The IRS adaptor
daptor proteins aid
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intracellular-signaling molecules and help specific proteins bind to appropriate receptors
[14]. The IRS recruit phosphoinositide-3-kinase to the cell membrane, where it
phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) into PIP3. This step
activates a protein kinase B-dependent pathway, which increases the metabolic effects of
insulin and also causes GLUT-4 glucose transporter proteins to be inserted into the cell
membranes of myofibers and adipocytes.
This pathway can be antagonized by hyperlipidemia. Lipids are broken down into
diacylglycerol, which physiologically activate protein kinase C (PKC) to phosphorylate
IRS on serine residues. This activation of serine, instead of tyrosine, phosphorylation
occurs upstream in the insulin signaling pathway and stops the signal from advancing,
contributing to insulin resistance.
Understanding these pathways is crucial to analyzing additional health risks and
creating both therapies and better diabetes management devices.

Health Risks
While IDDM and IIDM lead to many of the same health problems, IIDM is
much more prevalent, accounting for up to 90% of all diabetics [10]. Because poor health
and dieting have a strong association with these patients, it is necessary to understand
how these factors, especially dyslipidemia, impact the body’s signaling of insulin and the
relations of IIDM to insulin resistance.
Acutely, hyperglycemia is the buildup of glucose in the blood, which means cells
that rely on this glucose for energy sources are not getting it properly transported to them.
As a result, extra lipids are broken down into 2-carbon molecules, which are able to
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undergo cellular respiration and produce ATP [15]. This shift towards lipid metabolism
produces an increase in acetyl coenzyme A (acetyl-CoA), which is derived from fatty
acids. The additional acetyl-CoA that the mitochondria cannot metabolize is converted
into toxins called ketones. If this extreme hyperglycemic condition is not reversed,
diabetic ketoacidosis may occur which can put the patient into a diabetic coma [16].
Similar to ketoacidosis, diabetic hyperosmolar syndrome occurs when insulin
levels are slightly deficient, but lipolysis and ketogenesis are avoided [17]. While insulin
is present, it is not functioning properly, which inhibits the body from using either
glucose or fat for energy metabolism [16]. A hyperglycemic environment will still exist,
and even after the kidneys filter the blood, some excess glucose will be present in the
preurine. This decreases water reabsorption and will cause patients to urinate more
frequently [18]. If untreated, this syndrome may also lead to a diabetic coma and critical
dehydration levels.
These acute conditions can often be avoided with frequent blood-glucose
monitoring. Slight levels of transient hyperglycemia will occur naturally, but testing will
allow for earlier detection and quicker treatment. However, lengthened periods of
hyperglycemia over many years can cause chronic conditions such as cardiovascular
disease, retinopathy, nephropathy, neuropathy, and non-healing ulcers. Additionally,
IIDM is often associated with metabolic syndrome, a condition caused by diets with
elevated cholesterol and triglyceride levels [19]. Metabolic syndrome is diagnosed when
any three of the following three conditions are present: excess adiposity in the patient’s
midsection, dyslipidemia, decreased high-density lipoprotein (HDL) levels, hypertension,
and fasting hyperglycemia [19].
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While metabolic syndrome has varying pathophysiologies, the primary effects of
chronic hyperglycemia are due to endothelial dysfunction. Diabetic patients are shown to
have increased production of reactive oxygen species and decreased bioavailability of
endothelial nitric oxide [20]. As vascular superoxide (O2-) reacts with the lessened levels
of nitric oxide, it produces peroxynitrite (ONOO-) which inhibits receptors and enzymes
that remove free radicals [20]. Excess free radicals contribute to the vasoconstriction that
occurs in adverse cardiovascular diseases including atherosclerosis. The American Heart
Association attributes cardiovascular disease as the cause of death in at least 65% of
diabetic patients, and finds these same people to be two to four times more likely to
develop heart disease or have a stroke than non-diabetic adults [21].
Chronic hyperglycemia can also affect vision. Diabetic retinopathy, or a disorder
concerning the retina, is the most common condition [22]. Nonproliferative retinopathy
occurs when inflammation occludes the capillaries in the back of the eye. Vision loss is
rare at this stage, and often no treatment is necessary as long as the patient keeps better
control of their blood glucose fluctuations [23]. This condition can progress to
proliferative retinopathy when a large number of capillaries are occluded, stimulating
angiogenesis, or new capillary growth in the retina. Due to their immaturity, blood may
leak from newly formed capillaries, causing vitreous hemorrhage or scar tissue to form
[22]. Retinopathy at this stage may result in partial or total vision loss that may be
permanent.
Another common effect of diabetes is nephropathy. The nephron is the functional
unit of the kidney that is responsible for filtering blood. Chronic hyperglycemia causes
the kidneys to filter more blood, which damages them and makes the nephrons less
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efficient over time. Waste from the kidneys begins to leak and albumin is passed into the
urine [24]. Diabetic nephropathy is the leading cause of kidney failure in the United
States [25]. Because early-stage symptoms are often not shown, routine blood tests
should be conducted so specialists may diagnosis if a patient is at risk.
A final health risk is dyslipidemia, or increased levels of lipids and lipoproteins in
the blood. This can be caused by chronic hyperglycemia and insulin resistance over time.
Insulin resistance causes high triglyceride levels and increases production of very lowdensity lipoproteins (VLDL) and low-density lipoproteins (LDL), the pro-atherogenic
forms of cholesterol. Average levels of the anti-atherogenic cholesterol, HDL, are
decreased as they are rapidly depleted by transporting the excess LDL to the liver [26].
Excess LDL can pass through the endothelial layer and become oxidized and
endocytosed by macrophages, which transforms them into foam cells, causing
atherosclerosis and intimal thickening via hyperplasia, which can restrict blood
circulation [9].
These health risks, coupled with the number of existing and future patients,
necessitate more research be done to better understand and treat diabetes. The goal of this
research is to develop a laboratory protocol for BMED 460 students at Cal Poly, San Luis
Obispo. This protocol will lead students through a physiology experiment in which they
will determine the consistency of an oral glucose tolerance test (OGTT), and test the
hypothesis that lipid consumption increases insulin resistance. Upon completion of this
experiment, students will be able to describe how insulin signaling becomes impaired
when diacylglycerol levels rise and ultimately how IRS phosphorylation becomes
dysregulated.
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Chapter 2. Methods
Participants were five college-aged, non-diabetic students with no known health
conditions. Due to the length of each trial run, not every participant was involved in
every treatment.

Oral Glucose Tolerance Test
Oral glucose tolerance tests were performed similar to the clinical procedure
outlined by the National Health and Nutrition Examination Survey [27]. Participants
fasted for approximately nine hours before drinking a solution containing seventy-five
grams of glucose (Azer Scientific). In a hospital, the patient’s blood glucose level would
be tested via venipuncture two hours after the glucose treatment. For this experiment,
however, readings were taken in thirty minute intervals for three hours using a OneTouch
Ultra glucose meter where the subject would prick their finger with a lancet device and
use this blood for the measurement.

Lipid and Carbohydrate Treatments
After fasting between eight and ten hours, participants of the lipid treatment
consumed 16 ounces of 70% lean / 30% fat cooked ground beef, which included 136 g of
fat and 360 mg of cholesterol, or 208% and 120% of the respective daily recommended
values. Subjects fasted for three additional hours to allow for gastric clearance, at which
time the OGTT was performed as before [28].
Subjects in the carbohydrate treatment fasted for eight to ten hours, and then
consumed pasta made with white flour. This meal totaled 168 g of carbohydrates, or 56%

9

of the daily recommended value. The white flour acts as a source of simple carbohydrates
that will be transported to myofibers and hepatocytes to be stored as glycogen. After
consuming the pasta, subjects were not allowed to eat for one hour to give the stomach
time to void, after which the OGTT was performed as per to the two previous treatments
[29].
Statistical Analysis
The data is presented as mean ± standard. A one-way ANOVA test was
performed test the hypothesis that one of the treatments impaired glucose transport,
followed by a Tukey post hoc test.
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Chapter 3. Results
To create a representative curve, an OGTT with no additional treatments was
performed. Following glucose consumption, participants tested their blood sugar every
thirty minutes for three hours. Average values of the four trials are shown in Figure 3.
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Figure 3: Average glucose levels plotted against time.

As Figure 3 shows, a quick increase in glucose levels occurs during the first hour, after
which, levels steadily decline to the original baseline reading.
Once the OGTT’s consistency was established, the hypothesis that an increase of
lipids would increase insulin resistance was tested. The carbohydrate treatment was
included as a control for how insulin responds to an influx of carbohydrates with no
additional variables affecting insulin resistance. The average values from the lipid and
carbohydrate treatments are combined in Figure 4.
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Figure 4: Average glucose levels of the lipid (diamond) and carbohydrate (square) treatments
plotted against time.

The lipid values have the highest average glucose value at thirty minutes. They also seem
to have two slight “plateaus,” and at the final monitored time point, return close to the
initial baseline reading. The blood glucose levels following the carbohydrate treatment
were considerably higher and oscillated around 115 mg·dl-1 for the duration of the trial.
Statistical analysis was then performed to determine if the null hypothesis needed
to be rejected. A single factor ANOVA test calculated a p-value of 0.00675, showing that
a significant difference existed between at least two of the treatment groups. The
complete results of this test can be found in Table I located in Appendix A. A Tukey test
provided further analysis, and showed a significant difference existed between the
carbohydrate and dextrose treatments. No differences were found when comparing the
lipid test to either of the other treatments.
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Chapter 4. Discussion
Diabetes is being diagnosed with greater frequency in the United States. IIDM is
affecting over 25 million Americans, and is extending into younger age groups.
Hyperglycemia and dyslipidemia associated with this disease can cause fatal health
effects if left untreated over time. Previous studies, such as the one performed by The
Howard Hughes Medical Institute and Yale University School of Medicine, have studied
how free fatty acids effect the transportation of glucose to muscle tissue [26]. The
objective of this senior project was similar in that it analyzed the effects of dyslipidemia
on insulin resistance by performing OGTTs.
In order to analyze the effect of excess lipids, an OGTT had to be performed with
no additional treatments to show its consistency, Figure 3. The blood sugar levels peaked
at thirty minutes, and then steadily declined back to the baseline value at around two
hours. In a clinical setting, readings greater than 200 mg·dl-1 after two hours deem the
patient diabetic, although the test will be ran identically on a following day to ensure
correct results. If this reading falls between 140-199 mg·dl-1, the patient is considered to
be prediabetic and at serious risk of developing diabetes even if no other symptoms are
present [27].
With this consistency determined, the hypothesis that excess lipid levels increase
insulin resistance could be tested by comparing the results of an OGTT after a lipid-rich
and carbohydrate-rich meal was consumed.
The OGTT following ingestion of carbohydrates, Figure 4, resulted in fairly
horizontally linear values, neither showing a definitive peak nor declining to a normal
fasting glucose level. This may have been due to the fact that once insulin secretion is
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stimulated,
d, it takes only minutes for insulin to be secreted from β-cells,
cells, where it can then
activate glucose transport in myofibers and adipocytes. When this glucose stimulation
proceeds for longer than ten minutes, the insulin secretion quickly drops off and then
slowly increases again over the next hour [9], Figure 5.

Figure 5: Plasma insulin levels when exposed to constant elevated glucose. This graph illustrates
the initial insulin spike, followed by a drop and slower,
er, steady increase over time. This process
occurs when a constant treatment of glucose is being delivered to the system [9].
[9]

It takes about 10-15
15 minutes to consume the carbohydrate meal, and an additional
hour of fasting is allowed for gastric clearance. During this period,, the early
earl phase of
insulin release decreases,, and the slower, longer lasting late phase of ins
insulin
ulin release is
activated [9]. This late phase steadily increases for the hour in which subjects fasted
before the OGTT. This means insulin was consistently being secreted,, which led to the
fairly constant blood-glucose
lucose levels that were observed
observed.
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The OGTT following the lipid treatment showed the highest average value of 135
mg·dl-1 at the thirty minute mark. It also had two “plateaus,” and while it eventually
returned to the baseline reading, it took longer than the dextrose treatment to do so. A
possible explanation for this is that gastric emptying of a high-fat meal is decreased and
levels of glucagon-like peptide-1 (GLP-1) are increased [30]. One effect of slower gastric
emptying is that it takes longer for glucose to enter the stomach and circulate through the
body, which means that less insulin is released. For this senior project, this fact was
accounted for by the three hour wait time between consuming the lipid-rich meal and
performing the OGTT. The increase in GLP-1 may have factored into the decreasing
glucose levels of the lipid treatment as it neared the three hour testing mark. GLP-1,
which is secreted from L cells in the intestine, stimulates insulin secretion and inhibits
glucagon secretion; both of which lower blood glucose levels [30]. The increase of GLP1 was unaccounted for and may explain why no significant difference in blood sugar
levels existed between the lipid and other two treatments.
Another explanation for statistical differences not existing between the lipid and
carbohydrate treatments may have been that gastric emptying was not complete before
the OGTT of the carbohydrate treatment. Although subjects waited an hour after eating,
future tests should incorporate an additional thirty minutes of fasting. This adjustment
will hopefully keep the carbohydrate blood sugar levels fairly constant, but within a
lower range that may produce results significantly different from the lipids. If this
occurred, it would support the hypothesis that lipid-rich meals increase insulin resistance
through the phosphorylation of IRS onto serine amino acids instead of tyrosine amino
acids.
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Relevance to BMED 460
This study may be used to supplement the BMED 460 curriculum. While the
insulin pathways are already included in this course, these results provide additional
information on factors that affect insulin resistance and their compounding health effects
if diabetes is left untreated. If a lab is implemented, it will give students hands-on insight
to what diabetic patients must live through on a daily basis. With this disease being so
prevalent, this experience may stimulate students to develop treatments and innovate
existing medical devices.

Conclusion
This study was not able to support the hypothesis that lipid-rich meals increase
insulin resistance. However, there was evidence to suggest that some resistance was
occurring, and if this experiment was performed again, a few changes to the experimental
design can be suggested. Mainly, extend the post-carbohydrate consumption fasting
period to ninety minutes, and include a larger sample size of nondiabetic subjects.
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Appendix A – Statistical Data
Table I: Results for Single Factor ANOVA Test
Source
Factor
Error
Total

DF
2
18
20

S = 16.62

SS
3695
4970
8665

MS
1848
276

F
6.69

R-Sq = 42.65%

Level
Dextrose
Carbohydrates
Lipids

N
7
7
7

Mean
81.75
113.91
101.86

P
0.007

R-Sq(adj) = 36.27%

StDev
18.15
6.92
21.23

Individual 95% CIs For Mean Based on
Pooled StDev
----+---------+---------+---------+----(--------*-------)
(--------*--------)
(--------*--------)
----+---------+---------+---------+----75
90
105
120

Pooled StDev = 16.62

Table II: Results for Tukey Test
Grouping Information Using Tukey Method

Carbohydrates
Lipids
Dextrose

N
7
7
7

Mean
113.91
101.86
81.75

Grouping
A
A B
B

Means that do not share a letter are significantly different.

Dextrose subtracted from:
Lower Center
Carbohydrates
9.49
32.16
Lipids
-2.56
20.11

Upper
54.83
42.78

Carbohydrates subtracted from:
Lower Center Upper
Lipids
-34.72 -12.04 10.63

----+---------+---------+---------+----(--------*--------)
(--------*--------)
----+---------+---------+---------+-----25
0
25
50
----+---------+---------+---------+----(--------*--------)
----+---------+---------+---------+-----25
0
25
50

21

Appendix B – Student Protocol

OGTT and Insulin Signaling Pathway
In this experiment, you will explore type 2 diabetes and the insulin signaling pathway on a
macroscopic level by performing an Oral Glucose Tolerance Test (OGTT).

Background
Diabetes affects over 8% of the American population. Directly, it is the seventh leading cause of
death in the country. Indirectly, it is a primary factor of kidney failure, lower limb amputation,
and blindness, along with playing a role in hypertension and numerous cardiovascular
complications. It has become an epidemic and affects people of all ages. Type 2 diabetes, in
particular, is the most common and often avoidable form of this disease. Type 2 diabetics
experience insulin resistance which results in sustained elevated blood sugar levels.
This experiment will provide a review of the insulin signaling pathway to show how elevated
glucose levels promote insulin secretion, along with the mechanism insulin uses to metabolize
this excess glucose and help keep the body in homeostasis. Students will then get the chance to
undergo an OGTT. This is the same process hospitals use to screen patients who are believed to
be at risk of having or developing diabetes.
The hormone insulin is a primary factor in regulating blood sugar levels for all humans. Insulin is
produced by β-cells located in the endocrine portion of the pancreas, but what signals it to be
released into the blood stream? Glucose triggers the first signaling pathway which is responsible
for regulating insulin secretion (Figure 1). As the glucose travels through the blood, it uses a
GLUT-2 transporter in the liver to enter a β-cell. Once here, it uses a glucokinase (“glucose
sensor”) to phosphorylate G6P. More glucose means more available energy, which increases the
ATP:ADP ratio and closes ATP-sensitive potassium channels. Making these channels unavailable
causes the β-cell membrane to depolarize and upregulate calcium-ion channels. The main effect
of this is the exocytosis of insulin secretory granules from the β-cell out into the bloodstream.
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Figure 1: Cellular pathway depicting the events from glucose entering the β-cell
β
to insulin
secretion.
The goal of the OGTT is to expose the body to a large amount of gluc
glucose
ose in a short period of
time. The body then produce
produces and secretes insulin to naturally metabolize this excess sugar. This
willl be quantitatively measured using a glucose monitoring device
e at specified time intervals.
Naturally, there will be an in
initial spike in glucose levels. The key reading will occur
cur two hours
-1
after consumption. If a patient’s blood sugar is above 140 mgdl at this point, they may be
considered to have prediabetes and further testing will need to be performed.
Ultimately, this lab is trying to give engineering students first
first-hand
d exposure to some of the
routines diabetic patients have to commit to on a daily basis. With this experience, more and
more improvements to monitoring devices and regulatory drugs can be made. Ultimately this will
lead to fewer medical complications and h
hopefully
opefully fewer instances of the disease in the first
place.

Required
equired Equipment
•
•
•
•
•
•

Lancet Device
Lancets
Glucose Monitor
Glucose Monitor Test Strips (at least 7 per person)
Glucose Solution (1 per person)
Sanitizing Alcohol Wipes
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Procedure
Exercise: Oral Glucose Tolerance Test
1. Change the lancet. To do this, unscrew the top of the lancet device. Using a new lancet,
“cap” the old one already in the mechanism. The old one can be pulled straight out and
the new one inserted. To disconnect the two, move the old one in a circular motion until
it becomes loose and separates. Finally, screw the top of the lancet device back on.
Note: To prevent the possible spread of bloodborne pathogens, always
swap the lancet out for a new one.
2. Insert a test strip into the glucose meter. A number should appear, followed by a flashing
symbol which indicates it is ready to read a blood sample (Figure 2).

Figure 2: This flashing symbol indicates that the meter is ready to receive a blood sample.
3. Choose which finger will be pricked (They should be rotated for each test, and never use
the thumb), and clean the skin with an alcohol wipe. Wait a few seconds for the skin
surface to dry.
4. Pull back the slider on the lancet device to “arm” it. Hold it against the tip of the finger,
preferably on the side, and press in on the white button. The lancet will quickly project
outward and produce a small drop of blood (Figure 3). Note: Additional blood may need
to be squeezed out to adequately fill the test trip. If squeezing does not work, the depth
at which the lancet projects may be adjusted using the knob at the top of the lancet
device.

Figure 3: A drop of blood after using the lancet device on the side and tip of finger.
5. Slowly feed the drop of blood into the test strip. Once they come in contact with one
another, the test strip should act like a vacuum and “pull” the blood in.
6. The glucose meter will count down 5 seconds and then display a result. This number is
the blood sugar level measured in units of mgdl-1 (Figure 4). If the display shows
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“Er#,” this generally means not enough blood was gathered and an accurate reading
could not be made. Remove the test strip and repeat the above steps to record an
accurate measurement.

Figure 4: If all the previous steps are performed correctly, an accurate reading will look
like this.
7. This first value is the Baseline reading before any treatment has been applied and occurs
at “Time = 0 minutes.” After recording this first value, students will drink the solution of
75 mg of glucose. Blood sugar will then be tested every 30 minutes following steps 1-6
with the data being recorded in a table similar to this for each student:
Time
(min)

Glucose Level
(mgdl-1)

0
30
60
90
120
150
180

8. Because this experiment involves blood, make sure all surfaces remain clean and all used
materials are disposed of properly.

Analysis
1. Traditionally, a doctor will require the patient to fast for 8-10 hours before the OGTT is done.
Why is this important? If a meal is consumed two hours before the test, what may be some
effects it has on the results?
2. For the group’s data, plot the average values at each testing time point in Excel (Scatter plot
with smooth lines and markers). At what time is the glucose level the highest? The lowest?
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3. Here is the data for four patients that consumed a carbohydrate-rich meal one hour before
an OGTT:

Time

Trial #1

Trial #2

Trial #3

Trial #4

0

110

151

83

111

30

125

136

98

144

60

121

130

74

137

90

105

99

101

117

120

115

117

110

123

150

107

104

107

105

180

104

115

111

129

Do statistical differences exist at any time points between data from this test and what your
group recorded? What statistical test(s) did you use and why?

Figure Preparation
To complete the data analysis, create two figures to display your data. The first figure will be the
Excel plot of your group’s averaged data. The second figure will be an Excel plot of both your
average collected data and the average carbohydrate treatment data given in Problem 3. If
statistical significances exist, be sure to make note of them on the graph.
All bar charts must include a white background, standard error bars, no gridlines, axes labels,
legend (if necessary) within chart area, figure caption, no figure title, and statistical significance
indicated.

Laboratory Report
To complete the laboratory, you will write a laboratory report (less than 2 pages) that includes
introduction, methods, results, and discussion sections.
In the introduction section, you explain why a particular injury or disease-state is important to
study and how recruitment, summation, max force, and/or fatigue rate can be used to assess the
injury or disease state.
The methods should briefly describe how the data were collected, such that an experienced
researcher could repeat your experiments from the methods section alone.
The results should include your figures and objective conclusions of the data (i.e. what).
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The discussion section should include subjective interpretation(s) of the data (i.e. why),
explanations for any technical/methodological difficulties, and suggestions for future applications
of the utilized technique.
The report must also include a title, the team name, and all team members’ names in the upper
right-hand corner.
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